艾裡德克斯 IRIX 深 滬
等待開盤 09-30 09:30:00 美东时间
1.15
0.000
0.00%
華盛通- 最 高1.1797
- 今 開1.17
- 成交量 2.24万股
- 最 低 1.13
- 昨 收 1.15
- 總市值 1954.11万
- 52周最高 1.95
- 市盈率 靜 --
- 換手率 0.13%
- 52周最低 0.782
- 委 比 94.58%
- 總股本 1699.23万
- 歷史最高 16.64
- 量 比 0.33
- 振 幅 4.32%
- 歷史最低 0.782
- 每 手 1
- 風險率 0.46%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Iridex Regains Nasdaq Compliance by August 2025
Iridex ( ($IRIX) ) has issued an announcement. On May 14, 2025, Iridex Corporat...
09-10 04:50
Iridex regains Nasdaq listing compliance
Ophthalmic medical technology company, Iridex (NASDAQ:IRIX) on Tuesday said that it has received formal notice from Nasdaq confirming it has regained compliance with continued listing standards. The c...
09-10 04:42
Iridex Corporation Receives Formal Notification of Nasdaq Listing Compliance
Iridex Corporation has regained compliance with Nasdaq's continued listing standards after satisfying the minimum stockholders' equity requirement of $2.5 million, as evidenced by its quarterly report filed on August 12, 2025. The company had previously received a non-compliance notice in May 2025 but has now resolved the issue, and the matter is closed.
09-09 20:05
Iridex Q2 Sales $13.60M Up From $12.63M YoY
Iridex (NASDAQ:IRIX) reported $13.60 million in sales this quarter. This is a 7.67 percent increase over sales of $12.63 million the same period last year.
08-13 04:11
Earnings Scheduled For August 12, 2025
Companies Reporting Before The Bell • Smithfield Foods (NASDAQ:SFD) is expected...
08-12 16:32
Iridex to Report Second Quarter 2025 Financial Results on August 12, 2025
Iridex Corporation has announced plans to release its second-quarter 2025 financial results and provide a business update after the market close on August 12, 2025. The company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET for investors, accessible by dialing +1-888-596-4144 with passcode 2197032. A live and recorded webcast will be available on the company's website. Iridex is a leader in laser-based medical systems for glaucoma and...
07-29 20:05
Iridex Announces First Patient Enrolled in an Independent Landmark Investigator-Led UK Study Evaluating MicroPulse® Technology as an Adjunct to anti-VEGF Therapy for Diabetic Macular Edema
Iridex Corporation announced the initiation of the DAME Trial, an independent, investigator-led clinical study evaluating the addition of subthreshold MicroPulse laser therapy to anti-VEGF treatment for severe diabetic macular edema (DME). Led by Professor Noemi Lois at Queen’s University Belfast, the trial aims to enroll 264 participants across the UK to assess the clinical efficacy, safety, and cost-effectiveness of this combined approach. The ...
06-24 11:00
Iridex Amends Investor Rights Agreement with Novel
Iridex ( ($IRIX) ) has shared an announcement. On May 20, 2025, IRIDEX Corporat...
05-23 04:59
Iridex Faces Nasdaq Non-Compliance Notification
Iridex ( ($IRIX) ) has shared an update. On May 14, 2025, Iridex Corporation re...
05-21 05:48
Iridex Q1 GAAP EPS $(0.10) Up From $(0.21) YoY, Sales $11.90M Up From $11.76M YoY
Iridex (NASDAQ:IRIX) reported quarterly losses of $(0.10) per share. This is a 52.38 percent increase over losses of $(0.21) per share from the same period last year. The company reported $11.90 million in sales this
05-14 04:12
